GTF2H2C: A Potential Drug Target for Cancer and Other Diseases

Target Name: GTF2H2C

NCBI ID: G728340

GTF2H2C: A Potential Drug Target for Cancer and Other Diseases

GTF2H2C (GTF2H2D), also known as GLT-1, is a protein that is expressed in various tissues of the body, including the brain, heart, and kidneys. It is a key regulator of cell growth and differentiation, and has been linked to a number of diseases, including cancer.

Recent studies have identified GTF2H2C as a potential drug target for a number of diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. This is because GTF2H2C has been shown to play a role in the development and progression of these diseases, and in the regulation of their symptoms.

One of the key reasons for the potential of GTF2H2C as a drug target is its involvement in the regulation of cell growth and differentiation. GTF2H2C is a key regulator of the stem cell niche, and has been shown to control the proliferation and differentiation of stem cells into functional neurons and other cell types. This is important because stem cells are a promising therapeutic approach for a number of diseases, including cancer.

In addition to its role in stem cell biology, GTF2H2C has also been shown to be involved in the regulation of inflammation and immune response. This is important because inflammation and immune dysfunction have been implicated in a number of diseases, including autoimmune disorders and neurodegenerative diseases.

One of the key consequences of GTF2H2C's involvement in these processes is its potential to disrupt the development and progression of cancer. Studies have shown that GTF2H2C plays a role in the regulation of the angiogenic switch, which is the process by which cancer cells form blood vessels and access oxygen and nutrients. This is important because the angiogenic switch is often activated in cancer, and it allows cancer cells to grow and metastasize.

In addition to its potential as a drug target, GTF2H2C is also of interest as a biomarker for a number of diseases. This is because its expression has been shown to be associated with the development and progression of a number of diseases, including cancer. For example, studies have shown that high levels of GTF2H2C are associated with poor prognosis in patients with pancreatic cancer, and that its levels are also elevated in the brains of patients with Alzheimer's disease.

Overall, GTF2H2C is a protein that has the potential to be a drug target for a number of diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. Its involvement in stem cell biology and inflammation, as well as its potential as a biomarker, make it an attractive target for research and development of new treatments.

Protein Name: GTF2H2 Family Member C

Functions: Component of the core-TFIIH basal transcription factor involved in nucleotide excision repair (NER) of DNA and, when complexed to CAK, in RNA transcription by RNA polymerase II

More Common Targets